Virtus ETF Advisers’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-11,200
| Closed | -$240K | – | 528 |
|
|
2026
Q1 | $240K | Hold |
11,200
| – | – | 0.11% | 206 |
|
|
2025
Q4 | $104K | Buy |
+11,200
| New | +$93.6K | 0.05% | 326 |
|
|
2025
Q1 | – | Sell |
-27,296
| Closed | -$346K | – | 524 |
|
|
2024
Q4 | $346K | Buy |
27,296
+1,805
| +7% | +$25.1K | 0.14% | 205 |
|
|
2024
Q3 | $355K | Hold |
25,491
| – | – | 0.17% | 214 |
|
|
2024
Q2 | $351K | Buy |
25,491
+19,413
| +319% | +$284K | 0.17% | 198 |
|
|
2024
Q1 | $100K | Sell |
6,078
-414
| -6% | -$6.2K | 0.05% | 363 |
|
|
2023
Q4 | $94.8K | Sell |
6,492
-847
| -12% | -$10.3K | 0.06% | 384 |
|
|
2023
Q3 | $90K | Sell |
7,339
-734
| -9% | -$9.57K | 0.05% | 348 |
|
|
2023
Q2 | $96.4K | Buy |
8,073
+3,388
| +72% | +$44.2K | 0.06% | 401 |
|
|
2023
Q1 | $62.6K | Sell |
4,685
-1,797
| -28% | -$35.1K | 0.03% | 421 |
|
|
2022
Q4 | $139K | Sell |
6,482
-119
| -2% | -$2.44K | 0.07% | 367 |
|
|
2022
Q3 | $132K | Buy |
6,601
+50
| +0.8% | +$1.06K | 0.05% | 375 |
|
|
2022
Q2 | $117K | Sell |
6,551
-2,335
| -26% | -$24.1K | 0.04% | 391 |
|
|
2022
Q1 | $88K | Sell |
8,886
-527
| -6% | -$6.96K | 0.04% | 320 |
|
|
2021
Q4 | $159K | Buy |
+9,413
| New | +$193K | 0.06% | 327 |
|
Other funds holding DAWN
Virtus ETF Advisers's DAWN Position: Q2 2026 in Review
Virtus ETF Advisers sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 11,200 shares — an estimated $240K sold.
Virtus ETF Advisers first reported a position in DAWN in Q4 2021 and held it in 15 quarters. The position peaked at $355K in Q3 2024. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Virtus ETF Advisers reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Virtus ETF Advisers sold 11,200 Day One Biopharmaceuticals shares in Q2 2026, an estimated $240K.
- Virtus ETF Advisers first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 15 quarters.
- Virtus ETF Advisers's Day One Biopharmaceuticals position peaked at $355K in Q3 2024.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.